Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Study of Olomorasib with Standard Immunotherapy for Resected or Unresectable KRAS G12C-Mutant Non-Small Cell Lung Cancer A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety in Combination with Pembrolizumab or Durvalumab

Researchers are investigating whether olomorasib combined with pembrolizumab is more effective than pembrolizumab plus placebo for participants with resected KRAS G12C-mutant non-small cell lung cancer (NSCLC) in part A. In part B, they are assessing if olomorasib combined with durvalumab is more effective than durvalumab plus placebo for participants with unresectable KRAS G12C-mutant NSCLC. This Phase 3 study may last up to 3 years for each participant.

Age: 18Years +All GendersPhase 3
354 locations
Locarno Clinical Trials | DecenTrialz